Trial Profile
A Phase II/III Study of JNS020QD in Cancer Pain Patients - A Dose-Finding, Double-Blind Study of JNS020QD Compared With JNS005 in Patients Previously Untreated With Opioid Analgesics
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 27 May 2013
Price :
$35
*
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 15 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jul 2009 Actual patient numbers changed from 156 to 163 as reported by ClinicalTrials.gov.
- 05 Oct 2008 Status changed from recruiting to active, no longer recruiting as reported by CT.gov